BG108230A - Бензимидазоли, използвани за лечение на сексуална дисфункция - Google Patents

Бензимидазоли, използвани за лечение на сексуална дисфункция Download PDF

Info

Publication number: BG108230A
Authority: BG; Bulgaria
Prior art keywords: methyl; benzimidazole; piperazin; pyridin; hydrogen
Prior art date: 2001-03-09

Application number

BG108230A

Other languages

Bulgarian (bg)

English (en)

Inventor

Marlon Cowart

Pramila Bhatia

Jerome Daanen

Andrew Stewart

Teodozyj Kolasa

Jeffrey Rohde

Meena Patel

Jorge Brioni

Original Assignee

Abbott Laboratories

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-03-09

Filing date

2003-10-03

Publication date

2005-04-30

2001-06-05 Priority claimed from US09/874,484 external-priority patent/US20030008878A1/en

2003-10-03 Application filed by Abbott Laboratories filed Critical Abbott Laboratories

2005-04-30 Publication of BG108230A publication Critical patent/BG108230A/bg

Links

201000001880 Sexual dysfunction Diseases 0.000 title claims abstract description 74
231100000872 sexual dysfunction Toxicity 0.000 title claims abstract description 74
150000001556 benzimidazoles Chemical class 0.000 title 1
150000001875 compounds Chemical class 0.000 claims abstract description 269
238000011282 treatment Methods 0.000 claims abstract description 43
229910052739 hydrogen Inorganic materials 0.000 claims description 255
239000001257 hydrogen Substances 0.000 claims description 254
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 165
-1 cyano, formyl Chemical group 0.000 claims description 130
229910052736 halogen Inorganic materials 0.000 claims description 80
150000002367 halogens Chemical class 0.000 claims description 80
150000003839 salts Chemical class 0.000 claims description 75
125000000217 alkyl group Chemical group 0.000 claims description 73
239000000651 prodrug Substances 0.000 claims description 70
229940002612 prodrug Drugs 0.000 claims description 70
150000001408 amides Chemical class 0.000 claims description 64
150000002148 esters Chemical class 0.000 claims description 64
241000124008 Mammalia Species 0.000 claims description 61
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 50
125000004448 alkyl carbonyl group Chemical group 0.000 claims description 45
150000002431 hydrogen Chemical class 0.000 claims description 41
FRPJGTNLZNXQEX-UHFFFAOYSA-N 2-[[4-(2-pyridinyl)-1-piperazinyl]methyl]-1H-benzimidazole Chemical compound N=1C2=CC=CC=C2NC=1CN(CC1)CCN1C1=CC=CC=N1 FRPJGTNLZNXQEX-UHFFFAOYSA-N 0.000 claims description 38
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 36
125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 34
206010057671 Female sexual dysfunction Diseases 0.000 claims description 33
125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 31
NFCYVMDRDOBUCA-AWEZNQCLSA-N 2-[[(2s)-2-methyl-4-pyridin-2-ylpiperazin-1-yl]methyl]-1h-benzimidazole Chemical compound C([C@@H](N(CC1)CC=2NC3=CC=CC=C3N=2)C)N1C1=CC=CC=N1 NFCYVMDRDOBUCA-AWEZNQCLSA-N 0.000 claims description 25
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 25
125000003545 alkoxy group Chemical group 0.000 claims description 25
125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 25
229940095064 tartrate Drugs 0.000 claims description 25
125000004414 alkyl thio group Chemical group 0.000 claims description 21
NFCYVMDRDOBUCA-UHFFFAOYSA-N 2-[(2-methyl-4-pyridin-2-ylpiperazin-1-yl)methyl]-1h-benzimidazole Chemical compound C1CN(CC=2NC3=CC=CC=C3N=2)C(C)CN1C1=CC=CC=N1 NFCYVMDRDOBUCA-UHFFFAOYSA-N 0.000 claims description 20
IRHVKGPETODEAT-UHFFFAOYSA-N 2-[(4-phenylpiperazin-1-yl)methyl]-1h-benzimidazole Chemical compound N=1C2=CC=CC=C2NC=1CN(CC1)CCN1C1=CC=CC=C1 IRHVKGPETODEAT-UHFFFAOYSA-N 0.000 claims description 20
OTCBEARWFWNLRF-UHFFFAOYSA-N 2-[4-(1h-benzimidazol-2-ylmethyl)piperazin-1-yl]-1,3-thiazole Chemical compound N=1C2=CC=CC=C2NC=1CN(CC1)CCN1C1=NC=CS1 OTCBEARWFWNLRF-UHFFFAOYSA-N 0.000 claims description 20
STLDHJMNWBEBGX-UHFFFAOYSA-N 2-[[4-(2-ethoxyphenyl)piperazin-1-yl]methyl]-1h-benzimidazole Chemical compound CCOC1=CC=CC=C1N1CCN(CC=2NC3=CC=CC=C3N=2)CC1 STLDHJMNWBEBGX-UHFFFAOYSA-N 0.000 claims description 20
QKKFQHBDHBMWGM-UHFFFAOYSA-N 2-[[4-(2-methoxyphenyl)piperidin-1-yl]methyl]-1h-benzimidazole Chemical compound COC1=CC=CC=C1C1CCN(CC=2NC3=CC=CC=C3N=2)CC1 QKKFQHBDHBMWGM-UHFFFAOYSA-N 0.000 claims description 20
WINMXTNEPXMBLG-UHFFFAOYSA-N 2-[[4-(3-methylpyridin-2-yl)piperazin-1-yl]methyl]-1h-benzimidazole Chemical compound CC1=CC=CN=C1N1CCN(CC=2NC3=CC=CC=C3N=2)CC1 WINMXTNEPXMBLG-UHFFFAOYSA-N 0.000 claims description 20
VZEBBCOAASDUOG-UHFFFAOYSA-N 2-methylpropyl 2-[(4-pyridin-2-ylpiperazin-1-yl)methyl]benzimidazole-1-carboxylate Chemical compound N=1C2=CC=CC=C2N(C(=O)OCC(C)C)C=1CN(CC1)CCN1C1=CC=CC=N1 VZEBBCOAASDUOG-UHFFFAOYSA-N 0.000 claims description 20
JJQKBCIECKEMBR-UHFFFAOYSA-N 4-[4-(1h-benzimidazol-2-ylmethyl)piperazin-1-yl]phenol Chemical compound C1=CC(O)=CC=C1N1CCN(CC=2NC3=CC=CC=C3N=2)CC1 JJQKBCIECKEMBR-UHFFFAOYSA-N 0.000 claims description 20
AREKWDVNONIIPS-UHFFFAOYSA-N [2-[(4-pyridin-2-ylpiperazin-1-yl)methyl]benzimidazol-1-yl]-pyrrolidin-1-ylmethanone Chemical compound C1CN(C=2N=CC=CC=2)CCN1CC1=NC2=CC=CC=C2N1C(=O)N1CCCC1 AREKWDVNONIIPS-UHFFFAOYSA-N 0.000 claims description 20
125000004644 alkyl sulfinyl group Chemical group 0.000 claims description 20
DZNZGCABZHIRPU-UHFFFAOYSA-N 2-[(4-phenyl-3,6-dihydro-2h-pyridin-1-yl)methyl]-1h-benzimidazole Chemical compound N=1C2=CC=CC=C2NC=1CN(CC=1)CCC=1C1=CC=CC=C1 DZNZGCABZHIRPU-UHFFFAOYSA-N 0.000 claims description 19
DFYAIIXQJKVNLK-UHFFFAOYSA-N 2-[(4-pyridin-2-ylpiperidin-1-yl)methyl]-1h-benzimidazole Chemical compound N=1C2=CC=CC=C2NC=1CN(CC1)CCC1C1=CC=CC=N1 DFYAIIXQJKVNLK-UHFFFAOYSA-N 0.000 claims description 19
FXHHMDYNRLYBIP-UHFFFAOYSA-N 2-[4-(1h-benzimidazol-2-ylmethyl)piperazin-1-yl]benzonitrile Chemical compound N#CC1=CC=CC=C1N1CCN(CC=2NC3=CC=CC=C3N=2)CC1 FXHHMDYNRLYBIP-UHFFFAOYSA-N 0.000 claims description 19
GVEYDRPQIGZJMX-UHFFFAOYSA-N 2-[4-(1h-benzimidazol-2-ylmethyl)piperazin-1-yl]phenol Chemical compound OC1=CC=CC=C1N1CCN(CC=2NC3=CC=CC=C3N=2)CC1 GVEYDRPQIGZJMX-UHFFFAOYSA-N 0.000 claims description 19
ATPCXZFSRSVMMW-UHFFFAOYSA-N 2-[[4-(2-chlorophenyl)piperazin-1-yl]methyl]-1h-benzimidazole Chemical compound ClC1=CC=CC=C1N1CCN(CC=2NC3=CC=CC=C3N=2)CC1 ATPCXZFSRSVMMW-UHFFFAOYSA-N 0.000 claims description 19
APKCWCBYTWWSHR-UHFFFAOYSA-N 2-[[4-(2-fluorophenyl)piperazin-1-yl]methyl]-1h-benzimidazole Chemical compound FC1=CC=CC=C1N1CCN(CC=2NC3=CC=CC=C3N=2)CC1 APKCWCBYTWWSHR-UHFFFAOYSA-N 0.000 claims description 19
GRGYFXDAOZBGPF-UHFFFAOYSA-N 2-[[4-(2-methoxyphenyl)piperazin-1-yl]methyl]-1h-benzimidazole Chemical compound COC1=CC=CC=C1N1CCN(CC=2NC3=CC=CC=C3N=2)CC1 GRGYFXDAOZBGPF-UHFFFAOYSA-N 0.000 claims description 19
DIIMPNOBUZSQDU-UHFFFAOYSA-N 2-[[4-(3-fluoropyridin-2-yl)piperazin-1-yl]methyl]-1h-benzimidazole Chemical compound FC1=CC=CN=C1N1CCN(CC=2NC3=CC=CC=C3N=2)CC1 DIIMPNOBUZSQDU-UHFFFAOYSA-N 0.000 claims description 19
QXIHXJBCHQNHHK-UHFFFAOYSA-N 4,6-dibromo-2-[(4-pyridin-2-ylpiperazin-1-yl)methyl]-1h-benzimidazole Chemical compound N=1C2=CC(Br)=CC(Br)=C2NC=1CN(CC1)CCN1C1=CC=CC=N1 QXIHXJBCHQNHHK-UHFFFAOYSA-N 0.000 claims description 19
125000003342 alkenyl group Chemical group 0.000 claims description 19
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 19
UZJFFJHTJQGBFA-UHFFFAOYSA-N n-[2-[4-(1h-benzimidazol-2-ylmethyl)piperazin-1-yl]pyridin-3-yl]methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CN=C1N1CCN(CC=2NC3=CC=CC=C3N=2)CC1 UZJFFJHTJQGBFA-UHFFFAOYSA-N 0.000 claims description 19
125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 19
BZIHDTKDCIILSI-UHFFFAOYSA-N 2-[[4-(2-methylsulfanylphenyl)piperazin-1-yl]methyl]-1h-benzimidazole Chemical compound CSC1=CC=CC=C1N1CCN(CC=2NC3=CC=CC=C3N=2)CC1 BZIHDTKDCIILSI-UHFFFAOYSA-N 0.000 claims description 18
KEGYYRUXGXROQP-UHFFFAOYSA-N 2-[[4-(2-nitrophenyl)piperazin-1-yl]methyl]-1h-benzimidazole Chemical compound [O-][N+](=O)C1=CC=CC=C1N1CCN(CC=2NC3=CC=CC=C3N=2)CC1 KEGYYRUXGXROQP-UHFFFAOYSA-N 0.000 claims description 18
FLKJVYVXYMFZRE-UHFFFAOYSA-N 2-[[4-(6-methylpyridin-2-yl)piperazin-1-yl]methyl]-1h-benzimidazole Chemical compound CC1=CC=CC(N2CCN(CC=3NC4=CC=CC=C4N=3)CC2)=N1 FLKJVYVXYMFZRE-UHFFFAOYSA-N 0.000 claims description 18
125000005196 alkyl carbonyloxy group Chemical group 0.000 claims description 18
125000000304 alkynyl group Chemical group 0.000 claims description 18
CBDXXUZXRDBOGH-UHFFFAOYSA-N 6-[4-(1h-benzimidazol-2-ylmethyl)piperazin-1-yl]pyridin-3-ol Chemical compound N1=CC(O)=CC=C1N1CCN(CC=2NC3=CC=CC=C3N=2)CC1 CBDXXUZXRDBOGH-UHFFFAOYSA-N 0.000 claims description 17
125000003396 thiol group Chemical class [H]S* 0.000 claims description 17
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 16
239000003136 dopamine receptor stimulating agent Substances 0.000 claims description 16
125000001188 haloalkyl group Chemical group 0.000 claims description 16
125000002768 hydroxyalkyl group Chemical group 0.000 claims description 16
JBDSKBUSDDHPEB-UHFFFAOYSA-N n,n-dimethyl-2-[(4-pyridin-2-ylpiperazin-1-yl)methyl]benzimidazole-1-carboxamide Chemical compound N=1C2=CC=CC=C2N(C(=O)N(C)C)C=1CN(CC1)CCN1C1=CC=CC=N1 JBDSKBUSDDHPEB-UHFFFAOYSA-N 0.000 claims description 16
125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 16
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 15
XJHRQPODSUYKOJ-UHFFFAOYSA-N 2-[(4-pyrimidin-2-ylpiperazin-1-yl)methyl]-1h-benzimidazole Chemical compound N=1C2=CC=CC=C2NC=1CN(CC1)CCN1C1=NC=CC=N1 XJHRQPODSUYKOJ-UHFFFAOYSA-N 0.000 claims description 14
125000005129 aryl carbonyl group Chemical group 0.000 claims description 14
125000006254 cycloalkyl carbonyl group Chemical group 0.000 claims description 14
HSEIIOCMMFLOGG-UHFFFAOYSA-N 2-[4-(1h-benzimidazol-2-ylmethyl)piperazin-1-yl]pyridine-3-carbonitrile Chemical compound N#CC1=CC=CN=C1N1CCN(CC=2NC3=CC=CC=C3N=2)CC1 HSEIIOCMMFLOGG-UHFFFAOYSA-N 0.000 claims description 13
ZSKFERSPBICNGI-UHFFFAOYSA-N 6-fluoro-2-[(4-pyridin-2-ylpiperazin-1-yl)methyl]-1h-benzimidazole Chemical compound N=1C2=CC(F)=CC=C2NC=1CN(CC1)CCN1C1=CC=CC=N1 ZSKFERSPBICNGI-UHFFFAOYSA-N 0.000 claims description 12
208000010228 Erectile Dysfunction Diseases 0.000 claims description 12
201000001881 impotence Diseases 0.000 claims description 12
NFCYVMDRDOBUCA-CQSZACIVSA-N 2-[[(2r)-2-methyl-4-pyridin-2-ylpiperazin-1-yl]methyl]-1h-benzimidazole Chemical compound C([C@H](N(CC1)CC=2NC3=CC=CC=C3N=2)C)N1C1=CC=CC=N1 NFCYVMDRDOBUCA-CQSZACIVSA-N 0.000 claims description 11
125000004438 haloalkoxy group Chemical group 0.000 claims description 11
229910052757 nitrogen Inorganic materials 0.000 claims description 11
208000024172 Cardiovascular disease Diseases 0.000 claims description 10
208000018737 Parkinson disease Diseases 0.000 claims description 9
239000000674 adrenergic antagonist Substances 0.000 claims description 9
125000004656 alkyl sulfonylamino group Chemical group 0.000 claims description 9
239000003937 drug carrier Substances 0.000 claims description 9
229910052717 sulfur Inorganic materials 0.000 claims description 9
208000019022 Mood disease Diseases 0.000 claims description 8
229910052760 oxygen Inorganic materials 0.000 claims description 8
208000011117 substance-related disease Diseases 0.000 claims description 8
HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 claims description 7
GZPHSAQLYPIAIN-UHFFFAOYSA-N 3-pyridinecarbonitrile Chemical compound N#CC1=CC=CN=C1 GZPHSAQLYPIAIN-UHFFFAOYSA-N 0.000 claims description 7
208000024827 Alzheimer disease Diseases 0.000 claims description 7
208000019901 Anxiety disease Diseases 0.000 claims description 7
206010013654 Drug abuse Diseases 0.000 claims description 7
230000036506 anxiety Effects 0.000 claims description 7
229910052799 carbon Inorganic materials 0.000 claims description 7
125000000623 heterocyclic group Chemical group 0.000 claims description 7
229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 claims description 6
208000027866 inflammatory disease Diseases 0.000 claims description 6
239000002590 phosphodiesterase V inhibitor Substances 0.000 claims description 6
125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 claims description 3
125000000719 pyrrolidinyl group Chemical group 0.000 claims description 3
201000000980 schizophrenia Diseases 0.000 claims description 3
125000004204 2-methoxyphenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C([H])=C1[H] 0.000 claims description 2
208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims description 2
208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims description 2
208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims description 2
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
125000004356 hydroxy functional group Chemical group O* 0.000 claims 12
JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 claims 3
125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 2
SXOYXIOBQQZWBL-UHFFFAOYSA-N 4-phenyl-2,5-dihydropyridine Chemical compound C1C=NCC=C1C1=CC=CC=C1 SXOYXIOBQQZWBL-UHFFFAOYSA-N 0.000 claims 2
125000004198 2-fluorophenyl group Chemical group [H]C1=C([H])C(F)=C(*)C([H])=C1[H] 0.000 claims 1
239000000203 mixture Substances 0.000 abstract description 49
238000000034 method Methods 0.000 description 99
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 87
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 69
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 57
ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 50
241000282414 Homo sapiens Species 0.000 description 48
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 32
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 31
206010057672 Male sexual dysfunction Diseases 0.000 description 30
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 29
125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 29
239000000243 solution Substances 0.000 description 26
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 24
239000011541 reaction mixture Substances 0.000 description 24
102000005962 receptors Human genes 0.000 description 22
108020003175 receptors Proteins 0.000 description 22
238000004458 analytical method Methods 0.000 description 21
239000007787 solid Substances 0.000 description 21
239000000706 filtrate Substances 0.000 description 20
125000002887 hydroxy group Chemical group [H]O* 0.000 description 19
MRBFGEHILMYPTF-UHFFFAOYSA-N 1-(2-Pyrimidyl)piperazine Chemical compound C1CNCCN1C1=NC=CC=N1 MRBFGEHILMYPTF-UHFFFAOYSA-N 0.000 description 18
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical class CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 18
125000003785 benzimidazolyl group Chemical class N1=C(NC2=C1C=CC=C2)* 0.000 description 18
125000005843 halogen group Chemical group 0.000 description 18
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 18
239000000047 product Substances 0.000 description 18
229960004046 apomorphine Drugs 0.000 description 17
VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 17
229960003638 dopamine Drugs 0.000 description 17
239000011734 sodium Substances 0.000 description 17
208000035475 disorder Diseases 0.000 description 16
238000002844 melting Methods 0.000 description 16
230000008018 melting Effects 0.000 description 16
230000018052 penile erection Effects 0.000 description 16
235000019441 ethanol Nutrition 0.000 description 15
125000004093 cyano group Chemical group *C#N 0.000 description 14
239000003814 drug Substances 0.000 description 14
239000000843 powder Substances 0.000 description 14
BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 description 14
241000700159 Rattus Species 0.000 description 13
GRFNBEZIAWKNCO-UHFFFAOYSA-N 3-pyridinol Chemical compound OC1=CC=CN=C1 GRFNBEZIAWKNCO-UHFFFAOYSA-N 0.000 description 12
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 12
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 12
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 12
239000002904 solvent Substances 0.000 description 12
239000003981 vehicle Substances 0.000 description 12
SPMLMLQATWNZEE-UHFFFAOYSA-N 2-(chloromethyl)-1h-benzimidazole Chemical class C1=CC=C2NC(CCl)=NC2=C1 SPMLMLQATWNZEE-UHFFFAOYSA-N 0.000 description 11
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 11
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 10
FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 10
229910000024 caesium carbonate Inorganic materials 0.000 description 10
229940079593 drug Drugs 0.000 description 10
GZRKXKUVVPSREJ-UHFFFAOYSA-N pyridinylpiperazine Chemical compound C1CNCCN1C1=CC=CC=N1 GZRKXKUVVPSREJ-UHFFFAOYSA-N 0.000 description 10
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
241000282412 Homo Species 0.000 description 9
241001465754 Metazoa Species 0.000 description 9
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
206010047700 Vomiting Diseases 0.000 description 9
239000007924 injection Substances 0.000 description 9
238000002347 injection Methods 0.000 description 9
239000010410 layer Substances 0.000 description 9
238000003756 stirring Methods 0.000 description 9
239000000126 substance Substances 0.000 description 9
DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 9
230000008673 vomiting Effects 0.000 description 9
IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 8
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 8
238000000576 coating method Methods 0.000 description 8
230000000694 effects Effects 0.000 description 8
239000008194 pharmaceutical composition Substances 0.000 description 8
239000000741 silica gel Substances 0.000 description 8
229910002027 silica gel Inorganic materials 0.000 description 8
208000004483 Dyspareunia Diseases 0.000 description 7
206010020565 Hyperaemia Diseases 0.000 description 7
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 7
DRHKJLXJIQTDTD-OAHLLOKOSA-N Tamsulosine Chemical compound CCOC1=CC=CC=C1OCCN[C@H](C)CC1=CC=C(OC)C(S(N)(=O)=O)=C1 DRHKJLXJIQTDTD-OAHLLOKOSA-N 0.000 description 7
SECKRCOLJRRGGV-UHFFFAOYSA-N Vardenafil Chemical compound CCCC1=NC(C)=C(C(N=2)=O)N1NC=2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(CC)CC1 SECKRCOLJRRGGV-UHFFFAOYSA-N 0.000 description 7
125000003118 aryl group Chemical group 0.000 description 7
239000012267 brine Substances 0.000 description 7
125000000753 cycloalkyl group Chemical group 0.000 description 7
230000001856 erectile effect Effects 0.000 description 7
208000037869 female anorgasmia Diseases 0.000 description 7
238000003818 flash chromatography Methods 0.000 description 7
239000000546 pharmaceutical excipient Substances 0.000 description 7
IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 7
229960001289 prazosin Drugs 0.000 description 7
238000002360 preparation method Methods 0.000 description 7
229960003310 sildenafil Drugs 0.000 description 7
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 7
125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 7
229960002613 tamsulosin Drugs 0.000 description 7
229960001693 terazosin Drugs 0.000 description 7
VCKUSRYTPJJLNI-UHFFFAOYSA-N terazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1CCCO1 VCKUSRYTPJJLNI-UHFFFAOYSA-N 0.000 description 7
230000001225 therapeutic effect Effects 0.000 description 7
229960002381 vardenafil Drugs 0.000 description 7
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 6
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
125000004432 carbon atom Chemical group C* 0.000 description 6
239000003795 chemical substances by application Substances 0.000 description 6
239000002552 dosage form Substances 0.000 description 6
210000003016 hypothalamus Anatomy 0.000 description 6
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
231100000252 nontoxic Toxicity 0.000 description 6
230000003000 nontoxic effect Effects 0.000 description 6
239000000725 suspension Substances 0.000 description 6
FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 6
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 5
102000015554 Dopamine receptor Human genes 0.000 description 5
108050004812 Dopamine receptor Proteins 0.000 description 5
229920002472 Starch Polymers 0.000 description 5
239000004480 active ingredient Substances 0.000 description 5
230000008901 benefit Effects 0.000 description 5
210000004556 brain Anatomy 0.000 description 5
239000002775 capsule Substances 0.000 description 5
210000003169 central nervous system Anatomy 0.000 description 5
125000004966 cyanoalkyl group Chemical group 0.000 description 5
230000006735 deficit Effects 0.000 description 5
239000003085 diluting agent Substances 0.000 description 5
208000013403 hyperactivity Diseases 0.000 description 5
238000001727 in vivo Methods 0.000 description 5
230000003834 intracellular effect Effects 0.000 description 5
239000008101 lactose Substances 0.000 description 5
239000003921 oil Substances 0.000 description 5
235000019198 oils Nutrition 0.000 description 5
239000012044 organic layer Substances 0.000 description 5
125000004430 oxygen atom Chemical group O* 0.000 description 5
239000006187 pill Substances 0.000 description 5
229920001223 polyethylene glycol Polymers 0.000 description 5
238000000746 purification Methods 0.000 description 5
239000011780 sodium chloride Substances 0.000 description 5
239000007909 solid dosage form Substances 0.000 description 5
235000019698 starch Nutrition 0.000 description 5
239000003826 tablet Substances 0.000 description 5
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 5
IMRWILPUOVGIMU-UHFFFAOYSA-N 2-bromopyridine Chemical compound BrC1=CC=CC=N1 IMRWILPUOVGIMU-UHFFFAOYSA-N 0.000 description 4
KVCOOWROABTXDJ-UHFFFAOYSA-N 6-chloropyridin-3-ol Chemical compound OC1=CC=C(Cl)N=C1 KVCOOWROABTXDJ-UHFFFAOYSA-N 0.000 description 4
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 4
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
FEWJPZIEWOKRBE-LWMBPPNESA-L D-tartrate(2-) Chemical compound [O-]C(=O)[C@@H](O)[C@H](O)C([O-])=O FEWJPZIEWOKRBE-LWMBPPNESA-L 0.000 description 4
OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 4
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
229910004298 SiO 2 Inorganic materials 0.000 description 4
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
229930006000 Sucrose Natural products 0.000 description 4
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
238000010521 absorption reaction Methods 0.000 description 4
239000002253 acid Substances 0.000 description 4
102000030621 adenylate cyclase Human genes 0.000 description 4
108060000200 adenylate cyclase Proteins 0.000 description 4
239000000556 agonist Substances 0.000 description 4
150000001298 alcohols Chemical class 0.000 description 4
235000010443 alginic acid Nutrition 0.000 description 4
229920000615 alginic acid Polymers 0.000 description 4
239000008346 aqueous phase Substances 0.000 description 4
239000002585 base Substances 0.000 description 4
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
MUALRAIOVNYAIW-UHFFFAOYSA-N binap Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
125000004181 carboxyalkyl group Chemical group 0.000 description 4
125000004122 cyclic group Chemical group 0.000 description 4
239000006196 drop Substances 0.000 description 4
239000000284 extract Substances 0.000 description 4
238000001914 filtration Methods 0.000 description 4
LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 4
239000007788 liquid Substances 0.000 description 4
229910000069 nitrogen hydride Inorganic materials 0.000 description 4
239000012074 organic phase Substances 0.000 description 4
210000002963 paraventricular hypothalamic nucleus Anatomy 0.000 description 4
239000013641 positive control Substances 0.000 description 4
239000003755 preservative agent Substances 0.000 description 4
229920006395 saturated elastomer Polymers 0.000 description 4
230000009329 sexual behaviour Effects 0.000 description 4
239000008107 starch Substances 0.000 description 4
238000007920 subcutaneous administration Methods 0.000 description 4
125000001424 substituent group Chemical group 0.000 description 4
239000005720 sucrose Substances 0.000 description 4
238000003786 synthesis reaction Methods 0.000 description 4
CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 4
125000004853 tetrahydropyridinyl group Chemical class N1(CCCC=C1)* 0.000 description 4
238000004809 thin layer chromatography Methods 0.000 description 4
229910052723 transition metal Inorganic materials 0.000 description 4
239000000080 wetting agent Substances 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
229920001817 Agar Polymers 0.000 description 3
241000416162 Astragalus gummifer Species 0.000 description 3
XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 3
102000030782 GTP binding Human genes 0.000 description 3
108091000058 GTP-Binding Proteins 0.000 description 3
108010010803 Gelatin Proteins 0.000 description 3
241000282339 Mustela Species 0.000 description 3
206010028813 Nausea Diseases 0.000 description 3
229920001615 Tragacanth Polymers 0.000 description 3
239000000654 additive Substances 0.000 description 3
239000000443 aerosol Substances 0.000 description 3
235000010419 agar Nutrition 0.000 description 3
125000004183 alkoxy alkyl group Chemical group 0.000 description 3
125000005083 alkoxyalkoxy group Chemical group 0.000 description 3
125000005078 alkoxycarbonylalkyl group Chemical group 0.000 description 3
125000005138 alkoxysulfonyl group Chemical group 0.000 description 3
239000005557 antagonist Substances 0.000 description 3
239000007864 aqueous solution Substances 0.000 description 3
235000012216 bentonite Nutrition 0.000 description 3
125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 3
239000006172 buffering agent Substances 0.000 description 3
239000003054 catalyst Substances 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
FOCAUTSVDIKZOP-UHFFFAOYSA-N chloroacetic acid Chemical compound OC(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-N 0.000 description 3
229940106681 chloroacetic acid Drugs 0.000 description 3
238000001816 cooling Methods 0.000 description 3
230000003111 delayed effect Effects 0.000 description 3
239000006185 dispersion Substances 0.000 description 3
238000004090 dissolution Methods 0.000 description 3
229940052760 dopamine agonists Drugs 0.000 description 3
229940005501 dopaminergic agent Drugs 0.000 description 3
239000003995 emulsifying agent Substances 0.000 description 3
239000000839 emulsion Substances 0.000 description 3
239000000945 filler Substances 0.000 description 3
238000009472 formulation Methods 0.000 description 3
239000008273 gelatin Substances 0.000 description 3
229920000159 gelatin Polymers 0.000 description 3
235000019322 gelatine Nutrition 0.000 description 3
235000011852 gelatine desserts Nutrition 0.000 description 3
239000008187 granular material Substances 0.000 description 3
125000005842 heteroatom Chemical group 0.000 description 3
239000003701 inert diluent Substances 0.000 description 3
235000019359 magnesium stearate Nutrition 0.000 description 3
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 3
239000000463 material Substances 0.000 description 3
230000008693 nausea Effects 0.000 description 3
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 3
239000002674 ointment Substances 0.000 description 3
239000004006 olive oil Substances 0.000 description 3
235000008390 olive oil Nutrition 0.000 description 3
150000004885 piperazines Chemical class 0.000 description 3
229920000642 polymer Polymers 0.000 description 3
230000004044 response Effects 0.000 description 3
238000000926 separation method Methods 0.000 description 3
229910000029 sodium carbonate Inorganic materials 0.000 description 3
239000007858 starting material Substances 0.000 description 3
239000000375 suspending agent Substances 0.000 description 3
239000000454 talc Substances 0.000 description 3
229910052623 talc Inorganic materials 0.000 description 3
235000012222 talc Nutrition 0.000 description 3
125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
125000001544 thienyl group Chemical group 0.000 description 3
210000001519 tissue Anatomy 0.000 description 3
235000010487 tragacanth Nutrition 0.000 description 3
239000000196 tragacanth Substances 0.000 description 3
229940116362 tragacanth Drugs 0.000 description 3
150000003624 transition metals Chemical class 0.000 description 3
PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
NAWXUBYGYWOOIX-SFHVURJKSA-N (2s)-2-[[4-[2-(2,4-diaminoquinazolin-6-yl)ethyl]benzoyl]amino]-4-methylidenepentanedioic acid Chemical compound C1=CC2=NC(N)=NC(N)=C2C=C1CCC1=CC=C(C(=O)N[C@@H](CC(=C)C(O)=O)C(O)=O)C=C1 NAWXUBYGYWOOIX-SFHVURJKSA-N 0.000 description 2
NWKLWOGUAXAQGW-UHFFFAOYSA-N (6-chloropyridin-3-yl) acetate Chemical compound CC(=O)OC1=CC=C(Cl)N=C1 NWKLWOGUAXAQGW-UHFFFAOYSA-N 0.000 description 2
GEYOCULIXLDCMW-UHFFFAOYSA-N 1,2-phenylenediamine Chemical class NC1=CC=CC=C1N GEYOCULIXLDCMW-UHFFFAOYSA-N 0.000 description 2
YJRCDSXLKPERNV-UHFFFAOYSA-N 1-(2-nitrophenyl)piperazine Chemical compound [O-][N+](=O)C1=CC=CC=C1N1CCNCC1 YJRCDSXLKPERNV-UHFFFAOYSA-N 0.000 description 2
VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
KVNQCSIGNRPHHM-UHFFFAOYSA-N 2-piperidin-4-ylpyridine Chemical compound C1CNCCC1C1=CC=CC=N1 KVNQCSIGNRPHHM-UHFFFAOYSA-N 0.000 description 2
HTSNFXAICLXZMA-UHFFFAOYSA-N 3-(1-propyl-3-piperidinyl)phenol Chemical compound C1N(CCC)CCCC1C1=CC=CC(O)=C1 HTSNFXAICLXZMA-UHFFFAOYSA-N 0.000 description 2
206010067484 Adverse reaction Diseases 0.000 description 2
FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
239000004215 Carbon black (E152) Substances 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 2
108091006027 G proteins Proteins 0.000 description 2
241000206672 Gelidium Species 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
239000007818 Grignard reagent Substances 0.000 description 2
206010061218 Inflammation Diseases 0.000 description 2
229930195725 Mannitol Natural products 0.000 description 2
FEWJPZIEWOKRBE-XIXRPRMCSA-N Mesotartaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-XIXRPRMCSA-N 0.000 description 2
229920000168 Microcrystalline cellulose Polymers 0.000 description 2
229910019142 PO4 Inorganic materials 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 2
239000007983 Tris buffer Substances 0.000 description 2
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
230000000996 additive effect Effects 0.000 description 2
230000006838 adverse reaction Effects 0.000 description 2
239000000783 alginic acid Substances 0.000 description 2
229960001126 alginic acid Drugs 0.000 description 2
150000004781 alginic acids Chemical class 0.000 description 2
125000005093 alkyl carbonyl alkyl group Chemical group 0.000 description 2
125000006350 alkyl thio alkyl group Chemical group 0.000 description 2
208000026935 allergic disease Diseases 0.000 description 2
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 2
229910021529 ammonia Inorganic materials 0.000 description 2
230000003110 anti-inflammatory effect Effects 0.000 description 2
229960005070 ascorbic acid Drugs 0.000 description 2
239000011668 ascorbic acid Substances 0.000 description 2
239000012298 atmosphere Substances 0.000 description 2
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
239000000440 bentonite Substances 0.000 description 2
229910000278 bentonite Inorganic materials 0.000 description 2
SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 2
AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
125000002619 bicyclic group Chemical group 0.000 description 2
229920002988 biodegradable polymer Polymers 0.000 description 2
239000004621 biodegradable polymer Substances 0.000 description 2
230000037396 body weight Effects 0.000 description 2
239000000872 buffer Substances 0.000 description 2
239000011575 calcium Substances 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
150000001721 carbon Chemical group 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
235000010980 cellulose Nutrition 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
235000012343 cottonseed oil Nutrition 0.000 description 2
239000002385 cottonseed oil Substances 0.000 description 2
239000006071 cream Substances 0.000 description 2
UZVGSSNIUNSOFA-UHFFFAOYSA-N dibenzofuran-1-carboxylic acid Chemical group O1C2=CC=CC=C2C2=C1C=CC=C2C(=O)O UZVGSSNIUNSOFA-UHFFFAOYSA-N 0.000 description 2
235000014113 dietary fatty acids Nutrition 0.000 description 2
201000010099 disease Diseases 0.000 description 2
239000002270 dispersing agent Substances 0.000 description 2
238000009826 distribution Methods 0.000 description 2
239000008298 dragée Substances 0.000 description 2
230000002526 effect on cardiovascular system Effects 0.000 description 2
MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 2
229940093471 ethyl oleate Drugs 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
239000003885 eye ointment Substances 0.000 description 2
239000000194 fatty acid Substances 0.000 description 2
229930195729 fatty acid Natural products 0.000 description 2
235000003599 food sweetener Nutrition 0.000 description 2
125000002541 furyl group Chemical group 0.000 description 2
210000001035 gastrointestinal tract Anatomy 0.000 description 2
239000000499 gel Substances 0.000 description 2
235000001727 glucose Nutrition 0.000 description 2
239000008103 glucose Substances 0.000 description 2
150000004795 grignard reagents Chemical class 0.000 description 2
229960003878 haloperidol Drugs 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
229930195733 hydrocarbon Natural products 0.000 description 2
230000002055 immunohistochemical effect Effects 0.000 description 2
238000011065 in-situ storage Methods 0.000 description 2
230000004054 inflammatory process Effects 0.000 description 2
230000007794 irritation Effects 0.000 description 2
SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
239000003446 ligand Substances 0.000 description 2
239000002502 liposome Substances 0.000 description 2
230000004807 localization Effects 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
229910052943 magnesium sulfate Inorganic materials 0.000 description 2
235000019341 magnesium sulphate Nutrition 0.000 description 2
230000014759 maintenance of location Effects 0.000 description 2
239000000594 mannitol Substances 0.000 description 2
235000010355 mannitol Nutrition 0.000 description 2
IBIKHMZPHNKTHM-RDTXWAMCSA-N merck compound 25 Chemical compound C1C[C@@H](C(O)=O)[C@H](O)CN1C(C1=C(F)C=CC=C11)=NN1C(=O)C1=C(Cl)C=CC=C1C1CC1 IBIKHMZPHNKTHM-RDTXWAMCSA-N 0.000 description 2
108020004999 messenger RNA Proteins 0.000 description 2
125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 2
239000004530 micro-emulsion Substances 0.000 description 2
235000019813 microcrystalline cellulose Nutrition 0.000 description 2
239000008108 microcrystalline cellulose Substances 0.000 description 2
229940016286 microcrystalline cellulose Drugs 0.000 description 2
210000001577 neostriatum Anatomy 0.000 description 2
125000004433 nitrogen atom Chemical group N* 0.000 description 2
239000000346 nonvolatile oil Substances 0.000 description 2
210000001009 nucleus accumben Anatomy 0.000 description 2
150000007524 organic acids Chemical class 0.000 description 2
125000002524 organometallic group Chemical group 0.000 description 2
239000001301 oxygen Substances 0.000 description 2
229910052763 palladium Inorganic materials 0.000 description 2
239000006072 paste Substances 0.000 description 2
230000037361 pathway Effects 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
239000010452 phosphate Substances 0.000 description 2
150000003053 piperidines Chemical class 0.000 description 2
229940068196 placebo Drugs 0.000 description 2
239000000902 placebo Substances 0.000 description 2
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
229920001592 potato starch Polymers 0.000 description 2
210000003814 preoptic area Anatomy 0.000 description 2
239000003380 propellant Substances 0.000 description 2
125000003072 pyrazolidinyl group Chemical group 0.000 description 2
125000002755 pyrazolinyl group Chemical group 0.000 description 2
XACWJIQLDLUFSR-UHFFFAOYSA-N pyrrolidine-1-carbonyl chloride Chemical compound ClC(=O)N1CCCC1 XACWJIQLDLUFSR-UHFFFAOYSA-N 0.000 description 2
238000010992 reflux Methods 0.000 description 2
239000011347 resin Substances 0.000 description 2
229920005989 resin Polymers 0.000 description 2
239000008159 sesame oil Substances 0.000 description 2
235000011803 sesame oil Nutrition 0.000 description 2
RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 2
235000012239 silicon dioxide Nutrition 0.000 description 2
235000019333 sodium laurylsulphate Nutrition 0.000 description 2
MFRIHAYPQRLWNB-UHFFFAOYSA-N sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 2
239000008223 sterile water Substances 0.000 description 2
239000003206 sterilizing agent Substances 0.000 description 2
235000000346 sugar Nutrition 0.000 description 2
150000008163 sugars Chemical class 0.000 description 2
125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 2
239000011593 sulfur Substances 0.000 description 2
239000003765 sweetening agent Substances 0.000 description 2
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
230000000699 topical effect Effects 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
239000001993 wax Substances 0.000 description 2
LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
SKYZYDSNJIOXRL-BTQNPOSSSA-N (6ar)-6-methyl-5,6,6a,7-tetrahydro-4h-dibenzo[de,g]quinoline-10,11-diol;hydrochloride Chemical compound Cl.C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 SKYZYDSNJIOXRL-BTQNPOSSSA-N 0.000 description 1
HEVMDQBCAHEHDY-UHFFFAOYSA-N (Dimethoxymethyl)benzene Chemical compound COC(OC)C1=CC=CC=C1 HEVMDQBCAHEHDY-UHFFFAOYSA-N 0.000 description 1
108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
SPGKIJTUZIVUIZ-BTJKTKAUSA-N (z)-but-2-enedioic acid;2-[(4-pyridin-2-ylpiperazin-1-yl)methyl]-1h-benzimidazole Chemical compound OC(=O)\C=C/C(O)=O.N=1C2=CC=CC=C2NC=1CN(CC1)CCN1C1=CC=CC=N1 SPGKIJTUZIVUIZ-BTJKTKAUSA-N 0.000 description 1
FIARMZDBEGVMLV-UHFFFAOYSA-N 1,1,2,2,2-pentafluoroethanolate Chemical group [O-]C(F)(F)C(F)(F)F FIARMZDBEGVMLV-UHFFFAOYSA-N 0.000 description 1
JPRPJUMQRZTTED-UHFFFAOYSA-N 1,3-dioxolanyl Chemical group [CH]1OCCO1 JPRPJUMQRZTTED-UHFFFAOYSA-N 0.000 description 1
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
PWZDJIUQHUGFRJ-UHFFFAOYSA-N 1-(2-chlorophenyl)piperazine Chemical compound ClC1=CC=CC=C1N1CCNCC1 PWZDJIUQHUGFRJ-UHFFFAOYSA-N 0.000 description 1
FBQIUSDQWOLCNY-UHFFFAOYSA-N 1-(2-ethoxyphenyl)piperazine Chemical compound CCOC1=CC=CC=C1N1CCNCC1 FBQIUSDQWOLCNY-UHFFFAOYSA-N 0.000 description 1
IVTZRJKKXSKXKO-UHFFFAOYSA-N 1-(2-fluorophenyl)piperazine Chemical compound FC1=CC=CC=C1N1CCNCC1 IVTZRJKKXSKXKO-UHFFFAOYSA-N 0.000 description 1
VNZLQLYBRIOLFZ-UHFFFAOYSA-N 1-(2-methoxyphenyl)piperazine Chemical compound COC1=CC=CC=C1N1CCNCC1 VNZLQLYBRIOLFZ-UHFFFAOYSA-N 0.000 description 1
RXJURXTXLCOIDY-UHFFFAOYSA-N 1-(2-methylsulfanylphenyl)piperazine Chemical compound CSC1=CC=CC=C1N1CCNCC1 RXJURXTXLCOIDY-UHFFFAOYSA-N 0.000 description 1
HPYRNHPSWLCJKD-UHFFFAOYSA-N 1-(3-fluoropyridin-2-yl)piperazine Chemical compound FC1=CC=CN=C1N1CCNCC1 HPYRNHPSWLCJKD-UHFFFAOYSA-N 0.000 description 1
VVBVRZMTWMATNG-UHFFFAOYSA-N 1-(3-methylpyridin-2-yl)piperazine Chemical compound CC1=CC=CN=C1N1CCNCC1 VVBVRZMTWMATNG-UHFFFAOYSA-N 0.000 description 1
VOSMEFSBAHULFT-UHFFFAOYSA-N 1-(6-methylpyridin-2-yl)piperazine Chemical compound CC1=CC=CC(N2CCNCC2)=N1 VOSMEFSBAHULFT-UHFFFAOYSA-N 0.000 description 1
125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
KFLULAWRKIRNSP-UHFFFAOYSA-N 1-methyl-2-(4-pyridin-2-ylpiperazin-1-yl)benzimidazole Chemical compound Cn1c(nc2ccccc12)N1CCN(CC1)c1ccccn1 KFLULAWRKIRNSP-UHFFFAOYSA-N 0.000 description 1
FGYADSCZTQOAFK-UHFFFAOYSA-N 1-methylbenzimidazole Chemical compound C1=CC=C2N(C)C=NC2=C1 FGYADSCZTQOAFK-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
NKPMJJGLSFUOPK-UHFFFAOYSA-N 1-tert-butylpiperidin-4-one Chemical compound CC(C)(C)N1CCC(=O)CC1 NKPMJJGLSFUOPK-UHFFFAOYSA-N 0.000 description 1
YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 description 1
125000000453 2,2,2-trichloroethyl group Chemical group [H]C([H])(*)C(Cl)(Cl)Cl 0.000 description 1
125000003562 2,2-dimethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
YQTCQNIPQMJNTI-UHFFFAOYSA-N 2,2-dimethylpropan-1-one Chemical group CC(C)(C)[C]=O YQTCQNIPQMJNTI-UHFFFAOYSA-N 0.000 description 1
125000003660 2,3-dimethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
UNFCWWHNSUKYSH-UHFFFAOYSA-N 2-(chloromethyl)-6-fluoro-1h-benzimidazole Chemical compound FC1=CC=C2N=C(CCl)NC2=C1 UNFCWWHNSUKYSH-UHFFFAOYSA-N 0.000 description 1
HUHXLHLWASNVDB-UHFFFAOYSA-N 2-(oxan-2-yloxy)oxane Chemical class O1CCCCC1OC1OCCCC1 HUHXLHLWASNVDB-UHFFFAOYSA-N 0.000 description 1
125000003821 2-(trimethylsilyl)ethoxymethyl group Chemical group [H]C([H])([H])[Si](C([H])([H])[H])(C([H])([H])[H])C([H])([H])C(OC([H])([H])[*])([H])[H] 0.000 description 1
RXNZFHIEDZEUQM-UHFFFAOYSA-N 2-bromo-1,3-thiazole Chemical compound BrC1=NC=CS1 RXNZFHIEDZEUQM-UHFFFAOYSA-N 0.000 description 1
125000000143 2-carboxyethyl group Chemical group [H]OC(=O)C([H])([H])C([H])([H])* 0.000 description 1
AYPSHJCKSDNETA-UHFFFAOYSA-N 2-chloro-1h-benzimidazole Chemical compound C1=CC=C2NC(Cl)=NC2=C1 AYPSHJCKSDNETA-UHFFFAOYSA-N 0.000 description 1
SVAZIMBLBHOVIR-UHFFFAOYSA-N 2-chloro-3-fluoropyridine Chemical compound FC1=CC=CN=C1Cl SVAZIMBLBHOVIR-UHFFFAOYSA-N 0.000 description 1
QLUMNDLJGBUHPB-UHFFFAOYSA-N 2-chloro-5-phenylmethoxypyridine Chemical compound C1=NC(Cl)=CC=C1OCC1=CC=CC=C1 QLUMNDLJGBUHPB-UHFFFAOYSA-N 0.000 description 1
UZIXQYXXJBMILL-UHFFFAOYSA-N 2-chloro-6-fluoro-1h-benzimidazole Chemical compound FC1=CC=C2NC(Cl)=NC2=C1 UZIXQYXXJBMILL-UHFFFAOYSA-N 0.000 description 1
125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 1
MEQBJJUWDCYIAB-UHFFFAOYSA-N 2-chloropyridin-3-amine Chemical compound NC1=CC=CN=C1Cl MEQBJJUWDCYIAB-UHFFFAOYSA-N 0.000 description 1
125000001731 2-cyanoethyl group Chemical group [H]C([H])(*)C([H])([H])C#N 0.000 description 1
125000004777 2-fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 description 1
125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
JOMNTHCQHJPVAZ-UHFFFAOYSA-N 2-methylpiperazine Chemical compound CC1CNCCN1 JOMNTHCQHJPVAZ-UHFFFAOYSA-N 0.000 description 1
YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 1
229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
WQFWIVTXNKRNJZ-UHFFFAOYSA-N 2-piperazin-1-yl-1,3-thiazole Chemical compound C1CNCCN1C1=NC=CS1 WQFWIVTXNKRNJZ-UHFFFAOYSA-N 0.000 description 1
FRICBZWJFIRJOB-UHFFFAOYSA-N 2-piperazin-1-ylbenzonitrile Chemical compound N#CC1=CC=CC=C1N1CCNCC1 FRICBZWJFIRJOB-UHFFFAOYSA-N 0.000 description 1
UORNTHBBLYBAJJ-UHFFFAOYSA-N 2-piperazin-1-ylphenol Chemical compound OC1=CC=CC=C1N1CCNCC1 UORNTHBBLYBAJJ-UHFFFAOYSA-N 0.000 description 1
QSMNQUURWIAXAA-UHFFFAOYSA-N 2-piperazin-1-ylpyridine-3-carbonitrile Chemical compound N#CC1=CC=CN=C1N1CCNCC1 QSMNQUURWIAXAA-UHFFFAOYSA-N 0.000 description 1
125000001494 2-propynyl group Chemical group [H]C#CC([H])([H])* 0.000 description 1
UYWWLYCGNNCLKE-UHFFFAOYSA-N 2-pyridin-4-yl-1h-benzimidazole Chemical compound N=1C2=CC=CC=C2NC=1C1=CC=NC=C1 UYWWLYCGNNCLKE-UHFFFAOYSA-N 0.000 description 1
125000004975 3-butenyl group Chemical group C(CC=C)* 0.000 description 1
125000000474 3-butynyl group Chemical group [H]C#CC([H])([H])C([H])([H])* 0.000 description 1
NOIBKKGLBLZXPI-UHFFFAOYSA-N 3-fluoropyridine Chemical compound FC1=CC=C=N[CH]1 NOIBKKGLBLZXPI-UHFFFAOYSA-N 0.000 description 1
SBFGGYKKYLUTPD-UHFFFAOYSA-N 3-methyl-1-pyridin-2-ylpiperazine;hydrobromide Chemical compound Br.C1CNC(C)CN1C1=CC=CC=N1 SBFGGYKKYLUTPD-UHFFFAOYSA-N 0.000 description 1
125000003469 3-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
SRAVSVBVHDLLPO-UHFFFAOYSA-N 4-(2-methoxyphenyl)piperidine Chemical compound COC1=CC=CC=C1C1CCNCC1 SRAVSVBVHDLLPO-UHFFFAOYSA-N 0.000 description 1
KWEWNOOZQVJONF-UHFFFAOYSA-N 4-fluorobenzene-1,2-diamine Chemical compound NC1=CC=C(F)C=C1N KWEWNOOZQVJONF-UHFFFAOYSA-N 0.000 description 1
SJZRECIVHVDYJC-UHFFFAOYSA-N 4-hydroxybutyric acid Chemical compound OCCCC(O)=O SJZRECIVHVDYJC-UHFFFAOYSA-N 0.000 description 1
POGWXTJNUCZEPR-UHFFFAOYSA-N 4-phenyl-1,2,3,6-tetrahydropyridin-1-ium;chloride Chemical compound Cl.C1NCCC(C=2C=CC=CC=2)=C1 POGWXTJNUCZEPR-UHFFFAOYSA-N 0.000 description 1
GPEOAEVZTOQXLG-UHFFFAOYSA-N 4-piperazin-1-ium-1-ylphenolate Chemical compound C1=CC(O)=CC=C1N1CCNCC1 GPEOAEVZTOQXLG-UHFFFAOYSA-N 0.000 description 1
125000006043 5-hexenyl group Chemical group 0.000 description 1
QAJYCQZQLVENRZ-UHFFFAOYSA-N 6-chloropyridin-3-amine Chemical compound NC1=CC=C(Cl)N=C1 QAJYCQZQLVENRZ-UHFFFAOYSA-N 0.000 description 1
FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
239000005995 Aluminium silicate Substances 0.000 description 1
NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
235000017060 Arachis glabrata Nutrition 0.000 description 1
244000105624 Arachis hypogaea Species 0.000 description 1
235000010777 Arachis hypogaea Nutrition 0.000 description 1
235000018262 Arachis monticola Nutrition 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 1
206010055113 Breast cancer metastatic Diseases 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical compound CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 description 1
WHWLCVJZHZNTNY-UHFFFAOYSA-N CN1C2=CC=CC=C2N=C1N3CCC(CC3)C4=CC=CC=N4 Chemical compound CN1C2=CC=CC=C2N=C1N3CCC(CC3)C4=CC=CC=N4 WHWLCVJZHZNTNY-UHFFFAOYSA-N 0.000 description 1
MUALUVRJSYJFLB-LMECJBHSSA-N C[C@@H]1NCCNC1.C[C@H]1CN(CCN1)C1=NC=CC=C1 Chemical compound C[C@@H]1NCCNC1.C[C@H]1CN(CCN1)C1=NC=CC=C1 MUALUVRJSYJFLB-LMECJBHSSA-N 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
244000124209 Crocus sativus Species 0.000 description 1
235000015655 Crocus sativus Nutrition 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
235000019739 Dicalciumphosphate Nutrition 0.000 description 1
YIIMEMSDCNDGTB-UHFFFAOYSA-N Dimethylcarbamoyl chloride Chemical compound CN(C)C(Cl)=O YIIMEMSDCNDGTB-UHFFFAOYSA-N 0.000 description 1
229940098778 Dopamine receptor agonist Drugs 0.000 description 1
208000012661 Dyskinesia Diseases 0.000 description 1
239000001856 Ethyl cellulose Substances 0.000 description 1
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
240000007472 Leucaena leucocephala Species 0.000 description 1
235000010643 Leucaena leucocephala Nutrition 0.000 description 1
240000003183 Manihot esculenta Species 0.000 description 1
235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
239000012359 Methanesulfonyl chloride Substances 0.000 description 1
239000004909 Moisturizer Substances 0.000 description 1
GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
206010028980 Neoplasm Diseases 0.000 description 1
PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
CEFBXMNJODPQHJ-SPIKMXEPSA-N OC(=O)\C=C/C(O)=O.OC(=O)\C=C/C(O)=O.C=1N=C(C=2C=CC=CC=2)NC=1CN(CC1)CCN1C1=NC=CC=N1 Chemical compound OC(=O)\C=C/C(O)=O.OC(=O)\C=C/C(O)=O.C=1N=C(C=2C=CC=CC=2)NC=1CN(CC1)CCN1C1=NC=CC=N1 CEFBXMNJODPQHJ-SPIKMXEPSA-N 0.000 description 1
240000007817 Olea europaea Species 0.000 description 1
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
239000004952 Polyamide Substances 0.000 description 1
229920002732 Polyanhydride Polymers 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
229920000954 Polyglycolide Polymers 0.000 description 1
229920001710 Polyorthoester Polymers 0.000 description 1
241000288906 Primates Species 0.000 description 1
OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
208000028017 Psychotic disease Diseases 0.000 description 1
241000700157 Rattus norvegicus Species 0.000 description 1
SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
235000021307 Triticum Nutrition 0.000 description 1
244000098338 Triticum aestivum Species 0.000 description 1
102000011016 Type 5 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 description 1
108010037581 Type 5 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 description 1
240000008042 Zea mays Species 0.000 description 1
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
235000002017 Zea mays subsp mays Nutrition 0.000 description 1
239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
210000001015 abdomen Anatomy 0.000 description 1
230000003187 abdominal effect Effects 0.000 description 1
239000002250 absorbent Substances 0.000 description 1
230000002745 absorbent Effects 0.000 description 1
239000003655 absorption accelerator Substances 0.000 description 1
DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
125000001539 acetonyl group Chemical group [H]C([H])([H])C(=O)C([H])([H])* 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
230000009471 action Effects 0.000 description 1
WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
239000008272 agar Substances 0.000 description 1
229940072056 alginate Drugs 0.000 description 1
HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
235000012211 aluminium silicate Nutrition 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 1
210000004727 amygdala Anatomy 0.000 description 1
238000010171 animal model Methods 0.000 description 1
230000000507 anthelmentic effect Effects 0.000 description 1
239000000921 anthelmintic agent Substances 0.000 description 1
125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
229940125681 anticonvulsant agent Drugs 0.000 description 1
239000001961 anticonvulsive agent Substances 0.000 description 1
239000003429 antifungal agent Substances 0.000 description 1
229940121375 antifungal agent Drugs 0.000 description 1
239000002220 antihypertensive agent Substances 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
239000000164 antipsychotic agent Substances 0.000 description 1
229940005529 antipsychotics Drugs 0.000 description 1
239000002249 anxiolytic agent Substances 0.000 description 1
239000008135 aqueous vehicle Substances 0.000 description 1
229940009098 aspartate Drugs 0.000 description 1
125000003725 azepanyl group Chemical group 0.000 description 1
125000002393 azetidinyl group Chemical group 0.000 description 1
125000004069 aziridinyl group Chemical group 0.000 description 1
125000003828 azulenyl group Chemical group 0.000 description 1
230000006399 behavior Effects 0.000 description 1
238000005452 bending Methods 0.000 description 1
229940077388 benzenesulfonate Drugs 0.000 description 1
SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
DBFGMZALESGYRS-UHFFFAOYSA-N benzo[f][1]benzofuran Chemical compound C1=CC=C2C=C(OC=C3)C3=CC2=C1 DBFGMZALESGYRS-UHFFFAOYSA-N 0.000 description 1
229940050390 benzoate Drugs 0.000 description 1
125000000928 benzodioxinyl group Chemical group O1C(=COC2=C1C=CC=C2)* 0.000 description 1
125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 1
125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
125000004600 benzothiopyranyl group Chemical group S1C(C=CC2=C1C=CC=C2)* 0.000 description 1
125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 description 1
125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
CNTQPTBRKWUGFU-UHFFFAOYSA-N benzyl 4-hydroxy-4-pyridin-2-ylpiperidine-1-carboxylate Chemical compound C1CC(O)(C=2N=CC=CC=2)CCN1C(=O)OCC1=CC=CC=C1 CNTQPTBRKWUGFU-UHFFFAOYSA-N 0.000 description 1
VZOVOHRDLOYBJX-UHFFFAOYSA-N benzyl 4-oxopiperidine-1-carboxylate Chemical compound C1CC(=O)CCN1C(=O)OCC1=CC=CC=C1 VZOVOHRDLOYBJX-UHFFFAOYSA-N 0.000 description 1
SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 1
KCXMKQUNVWSEMD-UHFFFAOYSA-N benzyl chloride Chemical compound ClCC1=CC=CC=C1 KCXMKQUNVWSEMD-UHFFFAOYSA-N 0.000 description 1
229940073608 benzyl chloride Drugs 0.000 description 1
125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
230000002146 bilateral effect Effects 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
230000036983 biotransformation Effects 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
230000036772 blood pressure Effects 0.000 description 1
238000009835 boiling Methods 0.000 description 1
208000006218 bradycardia Diseases 0.000 description 1
244000309464 bull Species 0.000 description 1
235000019437 butane-1,3-diol Nutrition 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
235000010216 calcium carbonate Nutrition 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
235000012241 calcium silicate Nutrition 0.000 description 1
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
235000013539 calcium stearate Nutrition 0.000 description 1
239000008116 calcium stearate Substances 0.000 description 1
MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
150000004657 carbamic acid derivatives Chemical class 0.000 description 1
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
125000004623 carbolinyl group Chemical group 0.000 description 1
239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 1
239000002327 cardiovascular agent Substances 0.000 description 1
229940125692 cardiovascular agent Drugs 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000004359 castor oil Substances 0.000 description 1
235000019438 castor oil Nutrition 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
229920002301 cellulose acetate Polymers 0.000 description 1
210000003710 cerebral cortex Anatomy 0.000 description 1
229960000541 cetyl alcohol Drugs 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
229960004926 chlorobutanol Drugs 0.000 description 1
125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
150000005753 chloropyridines Chemical class 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
229940001468 citrate Drugs 0.000 description 1
239000004927 clay Substances 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
239000003086 colorant Substances 0.000 description 1
239000012141 concentrate Substances 0.000 description 1
235000008504 concentrate Nutrition 0.000 description 1
230000008602 contraction Effects 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
235000005822 corn Nutrition 0.000 description 1
235000005687 corn oil Nutrition 0.000 description 1
239000002285 corn oil Substances 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
239000013078 crystal Substances 0.000 description 1
150000005676 cyclic carbonates Chemical class 0.000 description 1
125000006637 cyclobutyl carbonyl group Chemical group 0.000 description 1
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000006639 cyclohexyl carbonyl group Chemical group 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000006255 cyclopropyl carbonyl group Chemical group [H]C1([H])C([H])([H])C1([H])C(*)=O 0.000 description 1
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
238000010511 deprotection reaction Methods 0.000 description 1
125000002576 diazepinyl group Chemical group N1N=C(C=CC=C1)* 0.000 description 1
WMKGGPCROCCUDY-PHEQNACWSA-N dibenzylideneacetone Chemical compound C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 WMKGGPCROCCUDY-PHEQNACWSA-N 0.000 description 1
NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
229940038472 dicalcium phosphate Drugs 0.000 description 1
229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
125000005883 dithianyl group Chemical group 0.000 description 1
230000003291 dopaminomimetic effect Effects 0.000 description 1
206010013663 drug dependence Diseases 0.000 description 1
238000009510 drug design Methods 0.000 description 1
238000007876 drug discovery Methods 0.000 description 1
230000004064 dysfunction Effects 0.000 description 1
239000003480 eluent Substances 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
239000002702 enteric coating Substances 0.000 description 1
238000009505 enteric coating Methods 0.000 description 1
210000001353 entorhinal cortex Anatomy 0.000 description 1
230000001257 erectogenic effect Effects 0.000 description 1
125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
DQYBDCGIPTYXML-UHFFFAOYSA-N ethoxyethane;hydrate Chemical compound O.CCOCC DQYBDCGIPTYXML-UHFFFAOYSA-N 0.000 description 1
VFRSADQPWYCXDG-LEUCUCNGSA-N ethyl (2s,5s)-5-methylpyrrolidine-2-carboxylate;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.CCOC(=O)[C@@H]1CC[C@H](C)N1 VFRSADQPWYCXDG-LEUCUCNGSA-N 0.000 description 1
235000019325 ethyl cellulose Nutrition 0.000 description 1
229920001249 ethyl cellulose Polymers 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
125000006125 ethylsulfonyl group Chemical group 0.000 description 1
125000004705 ethylthio group Chemical group C(C)S* 0.000 description 1
125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
230000029142 excretion Effects 0.000 description 1
239000003889 eye drop Substances 0.000 description 1
229940012356 eye drops Drugs 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
239000012065 filter cake Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
239000006260 foam Substances 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
239000012458 free base Substances 0.000 description 1
235000011087 fumaric acid Nutrition 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
229930195712 glutamate Natural products 0.000 description 1
YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
229940093915 gynecological organic acid Drugs 0.000 description 1
239000011121 hardwood Substances 0.000 description 1
230000036541 health Effects 0.000 description 1
230000000004 hemodynamic effect Effects 0.000 description 1
XVEOUOTUJBYHNL-UHFFFAOYSA-N heptane-2,4-diol Chemical compound CCCC(O)CC(C)O XVEOUOTUJBYHNL-UHFFFAOYSA-N 0.000 description 1
VHHHONWQHHHLTI-UHFFFAOYSA-N hexachloroethane Chemical compound ClC(Cl)(Cl)C(Cl)(Cl)Cl VHHHONWQHHHLTI-UHFFFAOYSA-N 0.000 description 1
BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
210000001320 hippocampus Anatomy 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
150000002430 hydrocarbons Chemical group 0.000 description 1
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
238000005984 hydrogenation reaction Methods 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
208000031424 hyperprolactinemia Diseases 0.000 description 1
230000002631 hypothermal effect Effects 0.000 description 1
125000002636 imidazolinyl group Chemical group 0.000 description 1
125000002883 imidazolyl group Chemical group 0.000 description 1
150000002466 imines Chemical class 0.000 description 1
125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
229940102223 injectable solution Drugs 0.000 description 1
229940102213 injectable suspension Drugs 0.000 description 1
208000014674 injury Diseases 0.000 description 1
230000010354 integration Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
210000001748 islands of calleja Anatomy 0.000 description 1
125000001977 isobenzofuranyl group Chemical group C=1(OC=C2C=CC=CC12)* 0.000 description 1
125000005990 isobenzothienyl group Chemical group 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
238000002955 isolation Methods 0.000 description 1
125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
239000007951 isotonicity adjuster Substances 0.000 description 1
125000003965 isoxazolidinyl group Chemical group 0.000 description 1
125000003971 isoxazolinyl group Chemical group 0.000 description 1
NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
230000003902 lesion Effects 0.000 description 1
230000002197 limbic effect Effects 0.000 description 1
210000003715 limbic system Anatomy 0.000 description 1
239000008297 liquid dosage form Substances 0.000 description 1
239000006194 liquid suspension Substances 0.000 description 1
239000006210 lotion Substances 0.000 description 1
VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
239000000347 magnesium hydroxide Substances 0.000 description 1
229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
150000002688 maleic acid derivatives Chemical class 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
210000001259 mesencephalon Anatomy 0.000 description 1
208000010658 metastatic prostate carcinoma Diseases 0.000 description 1
QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 1
125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 1
150000005217 methyl ethers Chemical class 0.000 description 1
125000006216 methylsulfinyl group Chemical group [H]C([H])([H])S(*)=O 0.000 description 1
125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
244000005700 microbiome Species 0.000 description 1
239000004005 microsphere Substances 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
230000001333 moisturizer Effects 0.000 description 1
125000002950 monocyclic group Chemical group 0.000 description 1
CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
125000002757 morpholinyl group Chemical group 0.000 description 1
201000003152 motion sickness Diseases 0.000 description 1
LWNKSGMYPMZZRL-UHFFFAOYSA-N n-(2-chloropyridin-3-yl)methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CN=C1Cl LWNKSGMYPMZZRL-UHFFFAOYSA-N 0.000 description 1
ALDFKRNWAIZKHT-UHFFFAOYSA-N n-(2-piperazin-1-ylpyridin-3-yl)methanesulfonamide Chemical compound CS(=O)(=O)NC1=CC=CN=C1N1CCNCC1 ALDFKRNWAIZKHT-UHFFFAOYSA-N 0.000 description 1
SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
125000001038 naphthoyl group Chemical group C1(=CC=CC2=CC=CC=C12)C(=O)* 0.000 description 1
125000001624 naphthyl group Chemical group 0.000 description 1
125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
230000003767 neural control Effects 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
235000001968 nicotinic acid Nutrition 0.000 description 1
239000011664 nicotinic acid Substances 0.000 description 1
239000012457 nonaqueous media Substances 0.000 description 1
239000002687 nonaqueous vehicle Substances 0.000 description 1
235000016709 nutrition Nutrition 0.000 description 1
230000035764 nutrition Effects 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
238000005457 optimization Methods 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
150000002895 organic esters Chemical class 0.000 description 1
125000001979 organolithium group Chemical group 0.000 description 1
125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
125000005963 oxadiazolidinyl group Chemical group 0.000 description 1
125000005882 oxadiazolinyl group Chemical group 0.000 description 1
125000001715 oxadiazolyl group Chemical group 0.000 description 1
125000000160 oxazolidinyl group Chemical group 0.000 description 1
125000005968 oxazolinyl group Chemical group 0.000 description 1
125000002971 oxazolyl group Chemical group 0.000 description 1
125000004043 oxo group Chemical group O=* 0.000 description 1
239000002245 particle Substances 0.000 description 1
235000020232 peanut Nutrition 0.000 description 1
235000021400 peanut butter Nutrition 0.000 description 1
125000006340 pentafluoro ethyl group Chemical group FC(F)(F)C(F)(F)* 0.000 description 1
229960004851 pergolide Drugs 0.000 description 1
YEHCICAEULNIGD-MZMPZRCHSA-N pergolide Chemical compound C1=CC([C@H]2C[C@@H](CSC)CN([C@@H]2C2)CCC)=C3C2=CNC3=C1 YEHCICAEULNIGD-MZMPZRCHSA-N 0.000 description 1
210000002509 periaqueductal gray Anatomy 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
239000003208 petroleum Substances 0.000 description 1
238000001050 pharmacotherapy Methods 0.000 description 1
239000012071 phase Substances 0.000 description 1
125000001791 phenazinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3N=C12)* 0.000 description 1
125000001484 phenothiazinyl group Chemical group C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
125000001644 phenoxazinyl group Chemical group C1(=CC=CC=2OC3=CC=CC=C3NC12)* 0.000 description 1
WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 1
YZTJYBJCZXZGCT-UHFFFAOYSA-N phenylpiperazine Chemical compound C1CNCCN1C1=CC=CC=C1 YZTJYBJCZXZGCT-UHFFFAOYSA-N 0.000 description 1
125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
230000035479 physiological effects, processes and functions Effects 0.000 description 1
YVUQSNJEYSNKRX-UHFFFAOYSA-N pimozide Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)CCCN1CCC(N2C(NC3=CC=CC=C32)=O)CC1 YVUQSNJEYSNKRX-UHFFFAOYSA-N 0.000 description 1
229960003634 pimozide Drugs 0.000 description 1
125000004193 piperazinyl group Chemical group 0.000 description 1
125000003386 piperidinyl group Chemical group 0.000 description 1
230000001817 pituitary effect Effects 0.000 description 1
229920000747 poly(lactic acid) Polymers 0.000 description 1
229920002647 polyamide Polymers 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
229920001296 polysiloxane Polymers 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000011148 porous material Substances 0.000 description 1
229910000027 potassium carbonate Inorganic materials 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
206010036596 premature ejaculation Diseases 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000000436 pro-erectile effect Effects 0.000 description 1
SSOLNOMRVKKSON-UHFFFAOYSA-N proguanil Chemical compound CC(C)\N=C(/N)N=C(N)NC1=CC=C(Cl)C=C1 SSOLNOMRVKKSON-UHFFFAOYSA-N 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
UFUASNAHBMBJIX-UHFFFAOYSA-N propan-1-one Chemical group CC[C]=O UFUASNAHBMBJIX-UHFFFAOYSA-N 0.000 description 1
125000006239 protecting group Chemical group 0.000 description 1
125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
125000003373 pyrazinyl group Chemical group 0.000 description 1
125000004076 pyridyl group Chemical group 0.000 description 1
230000001698 pyrogenic effect Effects 0.000 description 1
125000001422 pyrrolinyl group Chemical group 0.000 description 1
150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
IBBLRJGOOANPTQ-JKVLGAQCSA-N quinapril hydrochloride Chemical compound Cl.C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 IBBLRJGOOANPTQ-JKVLGAQCSA-N 0.000 description 1
125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
229940044601 receptor agonist Drugs 0.000 description 1
239000000018 receptor agonist Substances 0.000 description 1
238000001953 recrystallisation Methods 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
230000001020 rhythmical effect Effects 0.000 description 1
239000004248 saffron Substances 0.000 description 1
235000013974 saffron Nutrition 0.000 description 1
238000006748 scratching Methods 0.000 description 1
230000002393 scratching effect Effects 0.000 description 1
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
150000003334 secondary amides Chemical class 0.000 description 1
150000003335 secondary amines Chemical class 0.000 description 1
239000000932 sedative agent Substances 0.000 description 1
229940125723 sedative agent Drugs 0.000 description 1
230000001953 sensory effect Effects 0.000 description 1
210000002813 septal nuclei Anatomy 0.000 description 1
230000001568 sexual effect Effects 0.000 description 1
150000004760 silicates Chemical class 0.000 description 1
AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
239000001509 sodium citrate Substances 0.000 description 1
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
239000008247 solid mixture Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
239000003549 soybean oil Substances 0.000 description 1
235000012424 soybean oil Nutrition 0.000 description 1
239000007921 spray Substances 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
125000004434 sulfur atom Chemical group 0.000 description 1
239000013589 supplement Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
239000002278 tabletting lubricant Substances 0.000 description 1
IMCGHZIGRANKHV-AJNGGQMLSA-N tert-butyl (3s,5s)-2-oxo-5-[(2s,4s)-5-oxo-4-propan-2-yloxolan-2-yl]-3-propan-2-ylpyrrolidine-1-carboxylate Chemical compound O1C(=O)[C@H](C(C)C)C[C@H]1[C@H]1N(C(=O)OC(C)(C)C)C(=O)[C@H](C(C)C)C1 IMCGHZIGRANKHV-AJNGGQMLSA-N 0.000 description 1
RXSGZMPPLYKQFD-UHFFFAOYSA-N tert-butyl 4-(5-phenylmethoxypyridin-2-yl)piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1C(N=C1)=CC=C1OCC1=CC=CC=C1 RXSGZMPPLYKQFD-UHFFFAOYSA-N 0.000 description 1
125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
125000000037 tert-butyldiphenylsilyl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1[Si]([H])([*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
238000012360 testing method Methods 0.000 description 1
125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
125000005247 tetrazinyl group Chemical group N1=NN=NC(=C1)* 0.000 description 1
125000003831 tetrazolyl group Chemical group 0.000 description 1
230000000542 thalamic effect Effects 0.000 description 1
210000001103 thalamus Anatomy 0.000 description 1
230000004797 therapeutic response Effects 0.000 description 1
125000005304 thiadiazolidinyl group Chemical group 0.000 description 1
125000005305 thiadiazolinyl group Chemical group 0.000 description 1
125000001113 thiadiazolyl group Chemical group 0.000 description 1
125000001984 thiazolidinyl group Chemical group 0.000 description 1
125000002769 thiazolinyl group Chemical group 0.000 description 1
125000000335 thiazolyl group Chemical group 0.000 description 1
125000004568 thiomorpholinyl group Chemical group 0.000 description 1
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
239000003204 tranquilizing agent Substances 0.000 description 1
230000002936 tranquilizing effect Effects 0.000 description 1
230000008733 trauma Effects 0.000 description 1
125000004306 triazinyl group Chemical group 0.000 description 1
125000001425 triazolyl group Chemical group 0.000 description 1
IMNIMPAHZVJRPE-UHFFFAOYSA-N triethylenediamine Chemical compound C1CN2CCN1CC2 IMNIMPAHZVJRPE-UHFFFAOYSA-N 0.000 description 1
125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
210000002229 urogenital system Anatomy 0.000 description 1
238000003828 vacuum filtration Methods 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
235000019871 vegetable fat Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
210000001030 ventral striatum Anatomy 0.000 description 1
125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
125000001834 xanthenyl group Chemical group C1=CC=CC=2OC3=CC=CC=C3C(C12)* 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
- C07D235/14—Radicals substituted by nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Psychiatry (AREA)
Reproductive Health (AREA)
Pain & Pain Management (AREA)
Endocrinology (AREA)
Gynecology & Obstetrics (AREA)
Rheumatology (AREA)
Addiction (AREA)
Hospice & Palliative Care (AREA)
Psychology (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Heart & Thoracic Surgery (AREA)
Pregnancy & Childbirth (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Discharging, Photosensitive Material Shape In Electrophotography (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

BG108230A 2001-03-09 2003-10-03 Бензимидазоли, използвани за лечение на сексуална дисфункция BG108230A (bg)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US80353701A	2001-03-09	2001-03-09
US09/874,484 US20030008878A1 (en)	2001-03-09	2001-06-05	Benzimidazoles that are useful in treating sexual dysfunction
US10/017,939 US20020169166A1 (en)	2001-03-09	2001-12-14	Benzimidazoles that are useful in treating sexual dysfunction

Publications (1)

Publication Number	Publication Date
BG108230A true BG108230A (bg)	2005-04-30

Family

ID=27360930

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG108230A BG108230A (bg)	2001-03-09	2003-10-03	Бензимидазоли, използвани за лечение на сексуална дисфункция

Country Status (22)

Country	Link
US (1)	US20020169166A1 (cs)
EP (1)	EP1373220B1 (cs)
JP (1)	JP2005507370A (cs)
CN (1)	CN100430383C (cs)
AT (1)	ATE363474T1 (cs)
AU (1)	AU2002303128B2 (cs)
BG (1)	BG108230A (cs)
BR (1)	BR0205812A (cs)
CA (1)	CA2439943A1 (cs)
CZ (1)	CZ20032659A3 (cs)
DE (1)	DE60220385T2 (cs)
DK (1)	DK1373220T3 (cs)
ES (1)	ES2287278T3 (cs)
HU (1)	HUP0303413A3 (cs)
IL (1)	IL157457A0 (cs)
MX (1)	MXPA03008151A (cs)
NO (1)	NO326686B1 (cs)
NZ (1)	NZ527713A (cs)
PL (1)	PL371272A1 (cs)
SK (1)	SK12612003A3 (cs)
UY (1)	UY27203A1 (cs)
WO (1)	WO2002088093A1 (cs)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7022728B2 (en) *	2001-03-09	2006-04-04	Abbott Laboratories	Benzimidazoles that are useful in treating male sexual dysfunction
US6960589B2 (en)	2001-03-09	2005-11-01	Abbott Laboratories	Benzimidazoles that are useful in treating sexual dysfunction
US20040127504A1 (en) *	2002-09-06	2004-07-01	Cowart Marlon D.	Benzimidazoles that are useful in treating sexual dysfunction
PL1648874T3 (pl)	2003-07-30	2012-04-30	Xenon Pharmaceuticals Inc	Pochodne piperazyny i ich zastosowanie jako środków leczniczych
CA2533900A1 (en) *	2003-07-30	2005-02-10	Xenon Pharmaceuticals Inc.	Pyridyl derivatives and their use as therapeutic agents
AR045496A1 (es)	2003-08-29	2005-11-02	Schering Corp	Analolgos de benzimidazolpiperidinas 2- substiyuidas como antagonistas de los receptores de la hormona que concentra melanina selectivos para el tratamiento de la obesidad y trastornos relacionados
AU2005286647A1 (en)	2004-09-20	2006-03-30	Xenon Pharmaceuticals Inc.	Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
BRPI0515482A (pt)	2004-09-20	2008-07-22	Xenon Pharmaceuticals Inc	derivados heterocìclicos e seus usos como agentes terapêuticos
CN101084211A (zh)	2004-09-20	2007-12-05	泽农医药公司	杂环衍生物及其作为治疗剂的用途
AU2005286728A1 (en)	2004-09-20	2006-03-30	Xenon Pharmaceuticals Inc.	Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
MX2007003318A (es)	2004-09-20	2007-05-18	Xenon Pharmaceuticals Inc	Derivados heterociclicos y su uso como agentes terapeuticos.
MX2007003332A (es)	2004-09-20	2007-06-05	Xenon Pharmaceuticals Inc	Derivados heterociclicos y su uso como inhibidores de estearoil-coa-desaturasa.
BRPI0515500A (pt)	2004-09-20	2008-07-29	Xenon Pharmaceuticals Inc	derivados piridazina para inibição de estearoil-coa-desaturase
CA2618646A1 (en)	2005-06-03	2007-11-15	Xenon Pharmaceuticals Inc.	Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
WO2008079945A2 (en) *	2006-12-20	2008-07-03	University Of South Florida	Rock inhibitors and uses thereof
EP2149373A1 (en) *	2008-08-01	2010-02-03	Laboratorios Del. Dr. Esteve, S.A.	5HT7 receptor ligands and compositions comprising the same
EP2545905A1 (en)	2011-07-11	2013-01-16	Britannia Pharmaceuticals Limited	A new therapeutical composition containing apomorphine as active ingredient
KR102314286B1 (ko) *	2016-12-16	2021-10-21	화이자 인코포레이티드	Glp-1 수용체 작용제 및 이의 용도

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3362956A (en) *	1965-08-19	1968-01-09	Sterling Drug Inc	1-[(heterocyclyl)-lower-alkyl]-4-substituted-piperazines
FR2665161B1 (fr) *	1990-07-26	1992-11-27	Esteve Labor Dr	Nouveaux derives de benzimidazole, leur preparation et leur application en tant que medicaments.
GB9306578D0 (en) *	1993-03-30	1993-05-26	Merck Sharp & Dohme	Therapeutic agents
WO1997024334A1 (en) *	1995-12-28	1997-07-10	Fujisawa Pharmaceutical Co., Ltd.	Benzimidazole derivatives
GB9700878D0 (en) *	1997-01-17	1997-03-05	Scherer Ltd R P	Dosage forms and method for ameliorating male erectile dysfunction
CA2251255A1 (en) *	1998-10-20	2000-04-20	Mcgill University	The use of dopaminergic agents in the management of sexual dysfunction
ES2154605B1 (es) *	1999-09-14	2001-11-16	Univ Madrid Complutense	Nuevos derivados mixtos de bencimidazol-arilpiperazina con afinidad por los receptores serotoninergicos 5-ht1a y 5-ht3

2001
- 2001-12-14 US US10/017,939 patent/US20020169166A1/en not_active Abandoned
2002
- 2002-03-06 IL IL15745702A patent/IL157457A0/xx unknown
- 2002-03-06 MX MXPA03008151A patent/MXPA03008151A/es active IP Right Grant
- 2002-03-06 SK SK1261-2003A patent/SK12612003A3/sk not_active Application Discontinuation
- 2002-03-06 BR BR0205812-0A patent/BR0205812A/pt not_active IP Right Cessation
- 2002-03-06 CZ CZ20032659A patent/CZ20032659A3/cs unknown
- 2002-03-06 AU AU2002303128A patent/AU2002303128B2/en not_active Ceased
- 2002-03-06 NZ NZ527713A patent/NZ527713A/en unknown
- 2002-03-06 CA CA002439943A patent/CA2439943A1/en not_active Abandoned
- 2002-03-06 JP JP2002585395A patent/JP2005507370A/ja active Pending
- 2002-03-06 PL PL02371272A patent/PL371272A1/xx not_active Application Discontinuation
- 2002-03-06 AT AT02731130T patent/ATE363474T1/de not_active IP Right Cessation
- 2002-03-06 HU HU0303413A patent/HUP0303413A3/hu unknown
- 2002-03-06 DE DE60220385T patent/DE60220385T2/de not_active Expired - Lifetime
- 2002-03-06 WO PCT/US2002/007791 patent/WO2002088093A1/en not_active Ceased
- 2002-03-06 EP EP02731130A patent/EP1373220B1/en not_active Expired - Lifetime
- 2002-03-06 ES ES02731130T patent/ES2287278T3/es not_active Expired - Lifetime
- 2002-03-06 CN CNB028093828A patent/CN100430383C/zh not_active Expired - Fee Related
- 2002-03-06 DK DK02731130T patent/DK1373220T3/da active
- 2002-03-11 UY UY27203A patent/UY27203A1/es not_active Application Discontinuation
2003
- 2003-09-08 NO NO20033959A patent/NO326686B1/no not_active IP Right Cessation
- 2003-10-03 BG BG108230A patent/BG108230A/bg unknown

Also Published As

Publication number	Publication date
CN1516693A (zh)	2004-07-28
HUP0303413A2 (hu)	2004-01-28
CN100430383C (zh)	2008-11-05
ES2287278T3 (es)	2007-12-16
JP2005507370A (ja)	2005-03-17
BR0205812A (pt)	2005-05-03
SK12612003A3 (sk)	2004-04-06
ATE363474T1 (de)	2007-06-15
PL371272A1 (en)	2005-06-13
NO20033959D0 (no)	2003-09-08
HK1062174A1 (en)	2004-10-21
EP1373220B1 (en)	2007-05-30
US20020169166A1 (en)	2002-11-14
DK1373220T3 (da)	2007-10-08
EP1373220A1 (en)	2004-01-02
AU2002303128B2 (en)	2007-11-29
UY27203A1 (es)	2002-10-31
MXPA03008151A (es)	2004-03-16
WO2002088093A1 (en)	2002-11-07
NO20033959L (no)	2003-11-10
DE60220385D1 (de)	2007-07-12
IL157457A0 (en)	2004-03-28
CZ20032659A3 (cs)	2004-01-14
NZ527713A (en)	2006-09-29
HUP0303413A3 (en)	2007-08-28
NO326686B1 (no)	2009-01-26
DE60220385T2 (de)	2008-04-03
CA2439943A1 (en)	2002-11-07

Publication	Publication Date	Title
US6960589B2 (en)	2005-11-01	Benzimidazoles that are useful in treating sexual dysfunction
EP1373220B1 (en)	2007-05-30	Benzimidazoles that are useful in treating sexual dysfunction
US12479825B2 (en)	2025-11-25	Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof
RU2686323C2 (ru)	2019-04-25	Новые соединения и композиции для ингибирования fasn
BR112021002327A2 (pt)	2021-05-04	derivados de 6-(4-amino-3-metil-2-oxa-8-azaespiro[4,5]decan-8-il)-3-(2,3-diclorofenil)-2-metilpirimidin-4(3h)-ona e compostos relacionados como inibidores de ptpn11(shp2) para o tratamento do câncer
AU2002303128A1 (en)	2003-04-17	Benzimidazoles that are useful in treating sexual dysfunction
US20040127504A1 (en)	2004-07-01	Benzimidazoles that are useful in treating sexual dysfunction
EP2640708A1 (en)	2013-09-25	Heterocycle amines and uses thereof
BR112012011287A2 (pt)	2020-09-01	compostos inibidores de cinase, sua formulação farmacêutica e seus usos
CA2688326C (en)	2016-07-05	Tetrahydroisoquinolin-1-one derivative or salt thereof
US7351828B2 (en)	2008-04-01	Benzimidazoles that are useful in treating sexual dysfunction
US20030008878A1 (en)	2003-01-09	Benzimidazoles that are useful in treating sexual dysfunction
KR100863147B1 (ko)	2008-10-13	벤즈이미다졸 및 이를 포함하는 성 기능장애 치료용 약제학적 조성물
US20060009461A1 (en)	2006-01-12	Acetamides and benzamides that are useful in treating sexual dysfunction
HK1062174B (en)	2008-01-25	Benzimidazoles that are useful in treating sexual dysfunction
TW200401775A (en)	2004-02-01	Benzimidazoles that are useful in treating sexual dysfunction